BRCA1 and BRCA2 are tumour suppressor genes whose mutant phenotypes predispose to breast and ovarian cancer. Screening for mutations in these genes is now standard practice for hereditary breast and ovarian cancer (HBOC) cases in Europe, and permits medical follow-up and genetic counselling adapted to the needs of individuals in such families. Currently, most laboratories performing diagnostic analysis of the BRCA genes use PCR of exons and intron-exon boundaries coupled to a pre-screening step to identify anomalous amplicons. The techniques employed for the detection of mutations and SNPs have evolved over time and vary in sensitivity, specificity and cost-effectiveness. As a variant for pre-screening techniques, we chose the recently deve...
Mutations in BRCA1 and BRCA2 genes confer a high risk of breast and ovarian cancer. As such, their i...
Introduction: Currently, genetic testing of BRCA1/2 genes includes screening for single-nucleotide v...
Rapid and reliable identification of deleterious changes in the breast cancer genes BRCA1 and BRCA2 ...
Germ-line mutations of either BRCA1 or BRCA2 represents the major hereditary risk to breast and ovar...
Detection of mutations by DNA sequencing can be facilitated by scanning methods to identify amplicon...
Twenty-three percent of first diagnosed breast cancer patients resulted to be candidate for BRCA gen...
14 páginas, 4 figuras, 3 tablas.Mutational analysis of large multiexon genes without prevalent mutat...
The aim of this study was to implement the massively parallel sequencing technology for diagnostic a...
BRCA2 in a large number of samples is hampered by the large sizes of these genes and the scattering ...
International audienceRecent studies have revealed a significant proportion of BRCA1 exon deletions ...
Mutation detection sensitivity depends on the method employed and the type of mutation present. Melt...
Germ-line mutations in the BRCA1 gene cause hereditary predisposition to breast and ovarian cancer. ...
High throughput methods such as next generation sequencing are increasingly used in molecular diagno...
PARP inhibitors are used for treatment of tumors lacking function of the double-strand DNA break rep...
We examined 21 ovarian and 24 breastovarian cancer families with BRCA1 mutations among a Japanese po...
Mutations in BRCA1 and BRCA2 genes confer a high risk of breast and ovarian cancer. As such, their i...
Introduction: Currently, genetic testing of BRCA1/2 genes includes screening for single-nucleotide v...
Rapid and reliable identification of deleterious changes in the breast cancer genes BRCA1 and BRCA2 ...
Germ-line mutations of either BRCA1 or BRCA2 represents the major hereditary risk to breast and ovar...
Detection of mutations by DNA sequencing can be facilitated by scanning methods to identify amplicon...
Twenty-three percent of first diagnosed breast cancer patients resulted to be candidate for BRCA gen...
14 páginas, 4 figuras, 3 tablas.Mutational analysis of large multiexon genes without prevalent mutat...
The aim of this study was to implement the massively parallel sequencing technology for diagnostic a...
BRCA2 in a large number of samples is hampered by the large sizes of these genes and the scattering ...
International audienceRecent studies have revealed a significant proportion of BRCA1 exon deletions ...
Mutation detection sensitivity depends on the method employed and the type of mutation present. Melt...
Germ-line mutations in the BRCA1 gene cause hereditary predisposition to breast and ovarian cancer. ...
High throughput methods such as next generation sequencing are increasingly used in molecular diagno...
PARP inhibitors are used for treatment of tumors lacking function of the double-strand DNA break rep...
We examined 21 ovarian and 24 breastovarian cancer families with BRCA1 mutations among a Japanese po...
Mutations in BRCA1 and BRCA2 genes confer a high risk of breast and ovarian cancer. As such, their i...
Introduction: Currently, genetic testing of BRCA1/2 genes includes screening for single-nucleotide v...
Rapid and reliable identification of deleterious changes in the breast cancer genes BRCA1 and BRCA2 ...